z-logo
Premium
Update on the guideline of guidelines: non‐muscle‐invasive bladder cancer
Author(s) -
Taylor Jacob,
Becher Ezequiel,
Steinberg Gary D.
Publication year - 2020
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.14915
Subject(s) - bladder cancer , guideline , medicine , excellence , economic shortage , urothelial cancer , cancer , intensive care medicine , oncology , pathology , political science , linguistics , philosophy , government (linguistics) , law
Non‐muscle‐invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with frequent recurrences and risk of progression. Risk‐stratified treatment and surveillance protocols are often used to guide management. In 2017, BJUI reviewed guidelines on NMIBC from four major organizations: the American Urological Association/Society of Urological Oncology, the European Association of Urology, the National Comprehensive Cancer Network, and the National Institute for Health and Care Excellence. The present update will review major changes in the guidelines and broadly summarize new recommendations for treatment of NMIBC in an era of bacillus Calmette‐Guérin shortage and immense novel therapy development.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here